Badea Cristian T, Hedlund Laurence W, Qi Yi, Berridge Brian, Johnson G Allan
Center for In Vivo Microscopy, Duke University Medical Center, Durham, NC 27710, USA.
J Pharmacol Toxicol Methods. 2011 Sep-Oct;64(2):151-7. doi: 10.1016/j.vascn.2011.05.008. Epub 2011 Jun 13.
X-ray based digital subtraction angiography (DSA) is a common clinical imaging method for vascular morphology and function. Coronary artery characterization is one of its most important applications. We show that bi-plane DSA of rat coronary arteries can provide a powerful imaging tool for translational safety assessment in drug discovery.
A novel, dual tube/detector system, constructed explicitly for preclinical imaging, supports image acquisition at 10 frames/s with 88-micron spatial resolution. Ventilation, x-ray exposure, and contrast injection are all precisely synchronized using a biological sequence controller implemented as a LabVIEW application. A set of experiments were performed to test and optimize the sampling and image quality. We applied the DSA imaging protocol to record changes in the visualization of coronaries and myocardial perfusion induced by a vasodilator drug, nitroprusside. The drug was infused into a tail vein catheter using a peristaltic infusion pump at a rate of 0.07 mL/h for 3 min (dose: 0.0875 mg). Multiple DSA sequences were acquired before, during, and up to 25 min after drug infusion. Perfusion maps of the heart were generated in MATLAB to compare the drug effects over time.
The best trade-off between the injection time, pressure, and image quality was achieved at 60 PSI, with the injection of 150 ms occurring early in diastole (60 ms delay) and resulting in the delivery of 113 μL of contrast agent. DSA images clearly show the main branches of the coronary arteries in an intact, beating heart. The drug test demonstrated that DSA can detect relative changes in coronary circulation via perfusion maps.
The methodology for DSA imaging of rat coronary arteries can serve as a template for future translational studies to assist in safety evaluation of new pharmaceuticals. Although x-ray imaging involves radiation, the associated dose (0.4 Gy) is not a major limitation.
基于X射线的数字减影血管造影(DSA)是一种用于血管形态和功能的常见临床成像方法。冠状动脉特征分析是其最重要的应用之一。我们表明,大鼠冠状动脉的双平面DSA可为药物发现中的转化安全性评估提供强大的成像工具。
一种专门为临床前成像构建的新型双管/探测器系统,支持以10帧/秒的速度采集图像,空间分辨率为88微米。使用作为LabVIEW应用程序实现的生物序列控制器,精确同步通气、X射线曝光和造影剂注射。进行了一组实验来测试和优化采样及图像质量。我们应用DSA成像方案记录血管扩张剂硝普钠引起的冠状动脉可视化和心肌灌注变化。使用蠕动输液泵以0.07 mL/h的速率将药物注入尾静脉导管,持续3分钟(剂量:0.0875 mg)。在药物输注前、期间和输注后长达25分钟采集多个DSA序列。在MATLAB中生成心脏灌注图,以比较药物随时间的效果。
在60磅力/平方英寸(PSI)时,注射时间、压力和图像质量之间实现了最佳平衡,在舒张早期(延迟60毫秒)进行150毫秒的注射,从而输送113微升造影剂。DSA图像清晰显示完整跳动心脏中冠状动脉的主要分支。药物测试表明,DSA可通过灌注图检测冠状动脉循环的相对变化。
大鼠冠状动脉DSA成像方法可作为未来转化研究的模板,以协助新药物的安全性评估。尽管X射线成像涉及辐射,但相关剂量(0.4戈瑞)并非主要限制因素。